

nith Case Docket No. <u>GTN-001</u>

08/487,032 June 7, 1995

NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PLYORI FOR DIAGNOSTICS. AND THERAPEUTICS

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

Transmitted herewith for filing in connection with the above-identified application are the following:

- Response to Notice to File Missing Parts of Application (in duplicate)
- ☑ One executed Declaration, Petition and Power of Attorney
- ☑ Preliminary Amendment
- Sequence Listing substitute pages 76 through 782
- ▼ Transmittal Letter for Diskette for Sequence Listing
- ☑ Diskette Containing Sequence Listing
- **区** Copy of PTO Form 1533
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures
- Request for Three-Month Extension of Time (in duplicate)
- ☐ Check in the amount of \$860.00 (missing parts and surcharge fee)
- ☐ Check in the amount of \$900.00 (extension fee)
- ☐ Check in the amount of \$2488.00 (presentation of extra claims)
- ⊠ Return postcard

The fee has been calculated as shown below:

(Col. 1)					(Col. 2)		(Col. 3)	
		AIMS REMAINING ER AMENDMENT			GHEST NO. TOUSLY PAID FOR		PRESENT EXTRA	
TOTAL	*	87	MINUS	**	20	1	67	
INDEP.	*	16	MINUS	***	3	11	13	
☐ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM								

SMALL ENTITY					
RATE	ADDIT. FEE				
x 11 =	\$.00				
x 39 =	\$.00				
+125 =	\$.00				
TOTAL ADDIT. FEE	\$0.00				

OTHER THAN A SMALL ENTITY						
RATE	ADDIT. FEE					
x 22 =	\$ 1474.00					
x 78 =	\$ 1014.00					
+ 250 =	\$.00					
TOTAL	\$2488.00					

<u>OR</u>

<u>OR</u>

- * If the entry in Col 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

Amendment Transmittal Serial No. 08/487,032 Page 2

Please charge any additional fees or credit any overpayments associated with this communication to our Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on:

Date

Amy E Mandragouras, Reg. No. 36,20

Respectfully submitted,

LAHIVE & COCKFIELD

Amy E. Mandragouras

Reg. No. 36,207

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the application of: Smith, Douglas

Serial No.: 08/487,032

Filed: June 7, 1995

For: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER

PYLORI FOR DIAGNOSTICS AND THERAPEUTICS

Attorney Docket No.: GTN-001

Group Art Unit:

Examiner:

Assistant Commissioner for Patents BOX MISSING PARTS

Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents. Washington, D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

Amy E. Mandragouras Registration No. 36,207 Attorney for Applicant

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Dear Sir:

Responsive to the Notice to File Missing Parts of Application dated September 17, 1995,

Applicant's attorney submits herewith the executed Declaration, Petition and Power of Attorney

for Pate Application and a check in the amount of \$860.00 to cover the total amount owed by

Applicant including the \$130.00 surcharge and the \$730.00 basic filing fee. A Preliminary

Amendment, Sequence Listing in computer readable form as required by 37 CFR 1.821(e),

Sequence Listing as required under 37 CFR 1.821(c), a copyoff or polytograph a copy of

1.014.00 CK

1 103 1.474.00 CK Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures are also enclosed.

-2-

The Commissioner is hereby authorized to charge payment of any fees under 37 C.F.R. 1.16 and 1.17 during the pendency of this application or credit any overpayment to Deposit Account No. 12-0080.

Please charge any underpayments or credit any overpayments associated with this communication to our Deposit Account No. 12-0080. A duplicate of this letter is enclosed.

Respectfully submitted,

LAHIVE & COCKFIELD

Amy E. Mandragburas Registration No. 36,207 Attorney for Applicants

60 State Street Boston, MA 02109 Tel. (617) 227-7400

Dated: December 15, 1995



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Smith, Douglas

Serial No.: 08/487,032

Filed: June 7, 1995

For: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PYLORI FOR DIAGNOSTICS AND THERAPEUTICS

Attorney Docket No.: GTN-001

BOX SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

Group Art Unit:

Examiner:

TRANSMITTAL LETTER FOR DISKETTE OF SEQUENCE LISTING

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 17, 1995, we enclose a diskette which contains a computer readable form of the Sequence Listing for the above-referenced application. The Sequence Listing complies with the requirements of 37 C.F.R. §§1.821 and 1.825. The material on this diskette is identical in substance to the paper copy of the Sequence Listing which is submitted herewith. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirement of §1.824(d). No new matter has been added.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Sequence, Assistant Commissioner for Patents, Washington, DC 20231 on:

December 15, 1995

Amy E. Mandragouris, Reg. No. 36,207

Respectfully submitted,

LAHIVE & COCKFIELD

Amy E. Mandragouras

Reg. No. 36,207

60 State Street Boston, MA 0209

Tel. (617 227-7400

.*	₹'		Application No	
NUC	TICE TO COMPLY WITH REQUIREMENT CLEOTIDE SEQUENCE ÁND/OR AMINO	TS FOR PATENT APP ACID SEQUENCE D	PLICATIONS CON	ITAINING ,
The n	nucleotide and/or amino acid sequence disclosure co ach a disclosure as set forth in 37 CFR 1.821 - 1.825			requirements
	1. This application clearly fails to comply with the redirected to these regulations, published at 1114 OG	equirements of 37 CFR 1.82 29, May 15, 1990 and at 55	1 - 1.825. Applicant's 5 FR 18230, May 1, 199	attention is 90.
	2. This application does not contain, as a separate required by 37 CFR 1.821(c).	part of the disclosure on pag	per copy, a "Sequence	Listing" as
夕。	3. A copy of the "Sequence Listing" in computer rea	dable form has not been sui	bmitted as required by	37 CFR 1.321(e).
	4. A copy of the "Sequence Listing" in computer rea computer readable form does not comply with the reattached marked-up copy of the "Raw Sequence Listing".		ted. However, the con 2 and/or 1.823, as indic	tent of the rated on the
	 The computer readable form that has been filed wanteed as indicated on the attached CRF Diskett ubmitted as required by 37 CFR 1.825(d). 	rith this application has been te Problem Report. A substi	i found to be damaged tute computer readable	and/or form must be
☐ 6.	 The paper copy of the "Sequence Listing" is not the required by 37 CFR 1.821(e). 	ie same as the computer rea	adable form of the "Sec	uence Listing
.7.	. Other:			•
Applic	cant must provide:			
~	n initial or substitute computer readable form (CRF)	copy of the "Sequence Listin	- ng"	
1 1	n initial or substitute paper copy of the "Sequence Lispecification			into the
A s	statement that the content of the paper and compute w matter, as required by 37 CFR 1.821(e) or 1.821(f	er readable copies are the so or 1.821(g) or 1.825(b) or	ame and, where applic: 1.825(d)	able, include no
	estions regarding compliance with these r			
For Rul For CR	les Interpretation, call (703) 308-1123 F submission help, call (703) 308-4212 tentin software help, call (703) 308-6856	., -==	·.	

Please return a copy of this notice with your response.